Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria

Inclusion Criteria: * Genetically-confirmed progeria. * display clinical signs of progeria as per the clinical trial team. * currently receiving lonafarnib under protocol 09-06-0298 * have not experienced a grade 3 or 4 toxicity within two months preceding enrollment * willing and able to come to Boston for appropriate studies and examinations. * no recent fractures or major surgery (within four weeks) * Absolute poly count (Absolute neutrophil count + bands + monocytes) \>1,000/uL * platelets \>75,000/uL (transfusion independent) * hemoglobin \>9 g/dL * creatinine ≤ 1.5 times upper limit of normal (ULN) for age or Glomerular filtration rate (GFR) \>70 mL/min/1.73m2 * bilirubin ≤ 1.5x upper limit of normal for age * SGPT (ALT) \< and SGOT (AST) ≤ 2.5x normal range for age * serum albumin greater than or equal to 2 g/dL * PT/PTT: INR \<1.3 (or \<3 on anticoagulants) * Fasting LDL cholesterol within 1.5x ULN per institutional guidelines (ie, \<195 mg/dL for 2 - 18 years of age, \<240 mg/dL for subjects \>18 years old)\* and Fasting serum cholesterol \<300 mg/dL (\<7.75 mmol/L)\* and Fasting triglycerides \<2.5 ULN (\<325 mg/dL for ages 2 - 18, \<400 for ages \>18)\* \*may be re-evaluated for eligibility after initiation of lipid-lowering therapy * Signed informed consent according to institutional guidelines must be obtained and subject must begin therapy within twenty-eight (28) days. Exclusion Criteria: * Subjects must not be taking medications that significantly affect…